News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival with This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme



6/3/2013 12:31:20 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111’s in targeted cancer treatment. The company presented results from Phase I/II clinical study in patients with recurrent glioblastoma at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Data from the trial evaluating the effect of VB-111 on 28 patients with recurrent Glioblastoma Multiforme (rGBM) demonstrate that VB-111 was safe and well tolerated with repeat doses of up to 1x1013 VPs. Tumor responses and significant attenuation of tumor growth rate were seen. Overall survival was about 3 months longer compared to historical data in rGBM with the standard of care with anti-angiogenic agents.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES